Skip to main content
news
A Takeda logo is seen in its research hub in Cambridge, Massachusetts, U.S., November 26, 2018. REUTERS/Julie Steenhuysen

Cleary Gottlieb Steen & Hamilton has advised Japanese pharmaceutical giant Takeda on its planned acquisition of U.S.-based Nimbus Therapeutics' experimental psoriasis drug, with Goodwin Procter acting for the seller.

The deal value is expected to be up to $6 billion, reported Reuters. It added that the drug, codenamed "NDI-034858", has shown statistically significant reduction in moderate-to-severe psoriasis in a mid-stage study and is expected to enter late-stage trials next year.

The Goodwin team was led by partners Bill Collins, Sarah Solomon and Yasin Akbari in Boston, and Erini Svokos in New York.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

N&A, S&C, TMI advise as Japan's Nidec makes $1.6 bln bid for Makino Milling

by Asian Legal Business《亚洲法律杂志》 |

TMI Associates, Freshfields and Davis Polk & Wardwell have represented Japanese manufacturing giant Nidec on its 257-billion-yen ($1.6 billion) bid for Makino Milling Machine, which turned to Nishimura & Asahi and Sullivan & Cromwell for advice.

Deals

N&A, MHM, Skadden, STB guide JX Advanced Metal’s $3 bln Japan IPO

by Nimitt Dixit |

Nishimura & Asahi and Skadden Arps Slate Meagher & Flom are advising JX Advanced Metals on its upcoming 460-billion-yen ($3 billion) initial public offering, the largest listing in Japan since SoftBank Corp’s $23.5 billion IPO in 2018.

Deals

Trilegal, Touchstone, CAM act on Carlyle’s $400 mln entry into India auto-components space

by Nimitt Dixit |

Trilegal has advised global private equity firm Carlyle on its acquisition of majority stakes in Highway Industries (HIL) and Roop Automotives for $400 million, marking its entry into India's auto components sector through a new manufacturing platform.